lunsekimig

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
lunsekimig

GtoPdb Ligand ID: 14473

Synonyms: F027400161 [2] | SAR-443765 | SAR443765

Compound class: Antibody

Comment: Lunsekimig (SAR443765) is a single chain nanobody that is constructed of five linked antibody (V_HH) domains that simultaneously bind the inflammatory targets thymic stromal lymphopoietin (TSLP) and IL-13, and human serum albumin (ALB). The peptide sequence provided in the INN record matches SEQ ID No 1 in patent US11208476 [2], which equates to clone F027400161 therein.

References
1. Rogliani P, Manzetti GM, Bettin FR, D'Auria M, Calzetta L. (2024) Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review. Expert Opin Investig Drugs, 33 (1): 39-49. [PMID:38206116]
2. Rommelaere H, Brige A, Cornelis S, Dombrecht B, Lorent E, Rieger M, Soos T, Park J, Weigle B, Erb K. (2021) Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP. Patent number: US11208476B2. Assignee: Ablynx NV, Boehringer Ingelheim International GmbH, Sanofi SA. Priority date: 22/03/2021. Publication date: 28/12/2021.

References

1. Rogliani P, Manzetti GM, Bettin FR, D'Auria M, Calzetta L. (2024)
Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
Expert Opin Investig Drugs, 33 (1): 39-49. [PMID:38206116]

2. Rommelaere H, Brige A, Cornelis S, Dombrecht B, Lorent E, Rieger M, Soos T, Park J, Weigle B, Erb K. (2021)
Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP.
Patent number: US11208476B2. Assignee: Ablynx NV, Boehringer Ingelheim International GmbH, Sanofi SA. Priority date: 22/03/2021. Publication date: 28/12/2021.